CN109045077A - The anticancer usage of Heterostemonous Biebersteinia fat-soluble extract - Google Patents
The anticancer usage of Heterostemonous Biebersteinia fat-soluble extract Download PDFInfo
- Publication number
- CN109045077A CN109045077A CN201811006091.4A CN201811006091A CN109045077A CN 109045077 A CN109045077 A CN 109045077A CN 201811006091 A CN201811006091 A CN 201811006091A CN 109045077 A CN109045077 A CN 109045077A
- Authority
- CN
- China
- Prior art keywords
- biebersteinia
- extract
- heterostemonous
- platymiscium
- fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses purposes of the Heterostemonous Biebersteinia platymiscium fat-soluble extract in the drug of preparation prevention or treatment liver cancer, and new possibility is provided for clinical application.
Description
Technical field
The present invention relates to the new applications of Heterostemonous Biebersteinia fat-soluble extract.
Background technique
Heterostemonous Biebersteinia platymiscium is distributed in Mediterranean sea region, West Asia, the Central Asia, northwest China and western Himalaya, belongs to Gu Dizhong
Sea distribution.About 5 kinds of this category, it is distributed in Mediterranean sea region, West Asia, the Central Asia, northwest China and western Himalaya, belongs to Tethys point
Cloth.China records 3 kinds, is distributed in the Northwest and western Tibet.This category is more generally as independent Heterostemonous Biebersteinia
Belong to Biebersteinia to handle.The domestic frequently seen plants in China have Heterostemonous Biebersteinia Biebersteinia heterostemon
Maxim., split Heterostemonous Biebersteinia Biebersteinia multifida DC., high mountain Heterostemonous Biebersteinia Biebersteinia odora more
Steph.ex Fisch。
Heterostemonous Biebersteinia, is Tibetan areas characteristic nationality drug, and multi-section Tibetan classics are all on the books.It is recorded according to " Jingzhubencao ",
" Mang Jian " is bitter, trembles with fear, controls ulcer boils, and dissipating swollen analgesic has special efficacy.Currently, studying both at home and abroad Heterostemonous Biebersteinia platymiscium medicinal material less.
Summary of the invention
The purpose of the present invention is to provide the antineoplastic new usages of Heterostemonous Biebersteinia platymiscium.
Specifically, the present invention provides Heterostemonous Biebersteinia platymiscium fat-soluble extracts in preparation prevention or the drug for the treatment of liver cancer
In purposes.
Wherein, the drug is the drug for inhibiting liver cancer cell growth.
Wherein, fat-soluble extract is selected from the extract of nonpolar solvent.
Further, the polarity parameters of the nonpolar solvent are lower than 0.1.Polarity parameters of the present invention are conventional pole
Property parameter, in the representative solvent of non-polar and polar, with n-hexane for 0.0, water 10.2.Other solvent polarity parameters have,
Petroleum ether 0.01, hexane 0.06, hexamethylene 0.1, methylene chloride: 3.4, n-butanol: 3.7, propyl alcohol: 4.0, butyl acetate 4.0, four
Hydrogen furans: 4.2, chloroform: 4.1, ethyl acetate: 4.3, isopropanol 4.3, chloroform 4.4 etc..
It the use of petroleum ether is solvent in a specific embodiment of the invention.
Wherein, the extract the preparation method is as follows: the preparation method of the extract be selected from it is one of following:
Method one: Heterostemonous Biebersteinia platymiscium is taken, is directly extracted using nonpolar solvent, extract is prepared；
Method two: taking the ethanol extract of Heterostemonous Biebersteinia platymiscium, reuses nonpolar solvent and extracts, is prepared and mentions
Take object.
In the present invention, ethanol extract is the extract being prepared using conventional method using ethyl alcohol as solvent, at present
Also there is the preparation method of the ethanol extract.Ethyl alcohol generally selects concentration 80% or more, may further be 90% with
On ethyl alcohol, such as can be dehydrated alcohol, 95% ethyl alcohol.
In the present invention extracting method use conventional method, such as can be dipping, diacolation, reflux, ultrasound, microwave,
Flash, extraction etc..
When extraction, raw material can be crushed, it certainly, can also be without crushing.
The present invention also provides Heterostemonous Biebersteinia platymisciums or its extract in the drug that preparation inhibits liver cancer cell growth
Purposes.
Heretofore described Heterostemonous Biebersteinia platymiscium be selected from Heterostemonous Biebersteinia Biebersteinia heterostemon Maxim.,
Split Heterostemonous Biebersteinia Biebersteinia multifida DC., high mountain Heterostemonous Biebersteinia Biebersteinia odora Steph.ex more
One or both of Fisch.
The Heterostemonous Biebersteinia platymiscium that the present invention uses, can be used its all herbal medicine, can also use its aerial part.
Obviously, above content according to the present invention is not being departed from according to the ordinary technical knowledge and customary means of this field
Under the premise of the above-mentioned basic fundamental thought of the present invention, the modification, replacement or change of other diversified forms can also be made.
The specific embodiment of form by the following examples remakes further specifically above content of the invention
It is bright.But the range that this should not be interpreted as to the above-mentioned theme of the present invention is only limitted to example below.It is all to be based on above content of the present invention
The technology realized all belongs to the scope of the present invention.
Specific embodiment
The preparation of 1 ligroin extraction of embodiment
Heterostemonous Biebersteinia Biebersteinia heterostemon Maxim. is taken, after crushing, is directly added into petroleum ether, is flowed back
It extracts, extracting solution recycles petroleum ether solvent to get ligroin extraction.
The preparation of 2 ligroin extraction of embodiment
Take 95% ethanol extract of Heterostemonous Biebersteinia Biebersteinia heterostemon Maxim., as far as possible removing second
After alcohol, Soakage extraction is carried out using petroleum ether, extracting solution recycles petroleum ether solvent to get ligroin extraction.
The preparation of 3 ligroin extraction of embodiment
Take 95% ethanol extract of Heterostemonous Biebersteinia Biebersteinia heterostemon Maxim., as far as possible removing second
It after alcohol, is extracted using petroleum ether-water, takes petroleum ether layer recycling petroleum ether solvent to get ligroin extraction.
4 activity experiment of embodiment
1, culture solution is prepared
The culture of HepG2 cell selects RPMI-1640 culture medium, wherein containing 10% fetal calf serum and 1% culture
Base.
2, FBS is prepared
In the EP pipe that the FBS frozen is sub-packed in 15mL after melting at 4 DEG C, stored under the conditions of -20 DEG C.
3, HepG2 cell secondary culture
When the HepG2 cell of culture reached for 3~5 generation, the cell that upgrowth situation does not pollute well is chosen, is replaced fresh
Complete medium, remove culture medium within second day, with 3mL sterilizing 1 × PBS buffer solution rinse 3 times, 0.25% pancreatin digestion after
Add complete medium that cell suspension is made, then 1 000rpm is centrifuged 5min at room temperature, supernatant is removed, what addition was prepared in advance
Then frozen stock solution is divided in cryopreservation tube and seals, -80 DEG C of placements are placed on Liquid nitrogen storage for 24 hours.
4, cell cryopreservation and recovery
4.1 cell cryopreservations:
When the HepG2 cell of culture reached for 3~5 generation, the cell that upgrowth situation does not pollute well is chosen, is replaced fresh
Complete medium, outwell culture medium within second day, with 3mL sterilizing 1 × PBS buffer solution rinse several times, 0.25% pancreatin digestion
Afterwards plus cell suspension is made in complete medium, and then 1 000rpm is centrifuged 5min at room temperature, removes supernatant, is added and prepares in advance
Frozen stock solution, be then divided in cryopreservation tube and seal, -80 DEG C of placements are placed on Liquid nitrogen storage for 24 hours.
4.2 cell recoveries:
By the cryopreservation tube taken out in liquid nitrogen quickly be put into after sealing strip sealing orifice in 37 DEG C of water-baths shake back and forth with
Promote to melt, at this time it is noted that cell is not contaminated.After 75% cotton ball soaked in alcohol cleaning disinfection, 1 000rpm is centrifuged at room temperature
5min outwells the frozen stock solution in cryopreservation tube, and cell is transferred in culture bottle to (inoculating cell density is 4 × 105A/mL),
The complete medium for adding 10% is put into 37 DEG C of 5%CO2Incubator in cultivate, more renew immediately after second day cell is adherent
Culture medium.
5 cell proliferating determinings
With MTS method measurement Heterostemonous Biebersteinia different parts to the inhibiting effect of HepG2 cell.Choose the cell dissociation system in 3~7 generations
Obtain cell suspension (5 × 104A/mL), and every hole adds 100 μ L suspensions in 96 orifice plates, the sterilizing every hole 100 1 × PBS is added in surrounding
μL.Inoculated 96 orifice plate is put into 37 DEG C of 5%CO2Incubator in cultivate, after adherent, change the RPMI-1640 of serum-free
After culture medium synchronization process cell 12h, setting action time is for 24 hours.Water extract, n-butanol portion and petroleum ether part concentration
Gradient is respectively 10000,1000,100,10,0.1,0.01 μ g/mL, and after drug-treated, the MTS of 10 μ L is added to every hole
Solution continues culture plate to be incubated for 3 hours in incubator.The absorbance at 450nm is measured with microplate reader, and uses blank well
Zeroing.The inhibiting rate of cell is calculated with following calculation formula:
Inhibiting rate (%)=[1- (ADrug-ABlank)/(AControl-ABlank)]
ADrug: various concentration treated absorbance
AControl: without the cell hole absorbance of drug-treated
ABlank: only add the absorbance of MTS and culture medium
6 experimental results
Each extract is shown in Table 1 to the inhibitory effect of HepG2 cell:
Table 1
As can be seen from the above table, using water extract, under the concentration of 1000 μ g/mL, certain inhibition makees liver cancer cells
With；And n-butanol extract, ligroin extraction are used, under the concentration of 1000 μ g/mL, be able to reach 70.99%,
96.05% inhibiting rate.
N-butanol portion, water extract in the present invention, be all extracted according to systematic solvent extraction it is obtained, that is, use solvent pole
The sequence of property from low to high once extracts.
Claims (9)
1. purposes of the Heterostemonous Biebersteinia platymiscium fat-soluble extract in the drug of preparation prevention or treatment liver cancer.
2. purposes according to claim 1, it is characterised in that: the drug is the drug for inhibiting liver cancer cell growth.
3. purposes according to claim 1, it is characterised in that: the fat-soluble extract is selected from the extraction of nonpolar solvent
Object.
4. purposes according to claim 3, it is characterised in that: the polarity parameters of the organic solvent are lower than 0.1.
5. purposes according to claim 3 or 4, it is characterised in that: the nonpolar solvent is selected from petroleum ether.
6. purposes according to claim 3, it is characterised in that: the preparation method of the extract is selected from one of following:
Method one: Heterostemonous Biebersteinia platymiscium is taken, is directly extracted using nonpolar solvent, extract is prepared；
Method two: taking the ethanol extract of Heterostemonous Biebersteinia platymiscium, reuses nonpolar solvent and extracts, and extraction is prepared
Object.
7. purposes according to claim 6, it is characterised in that: the ethanol extract refers to 80% or more concentration
The extract that ethyl alcohol is prepared as solvent.
8. purposes of the Heterostemonous Biebersteinia platymiscium fat-soluble extract in the drug that preparation inhibits liver cancer cell growth.
9. purposes described in any one according to claim 1~8, it is characterised in that: the Heterostemonous Biebersteinia platymiscium, which is selected from, to be smoked
Ox Biebersteinia heterostemon Maxim., split Heterostemonous Biebersteinia Biebersteinia multifida DC., height more
One or both of mountain Heterostemonous Biebersteinia Biebersteinia odora Steph.ex Fisch.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811006091.4A CN109045077A (en) | 2018-08-30 | 2018-08-30 | The anticancer usage of Heterostemonous Biebersteinia fat-soluble extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811006091.4A CN109045077A (en) | 2018-08-30 | 2018-08-30 | The anticancer usage of Heterostemonous Biebersteinia fat-soluble extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109045077A true CN109045077A (en) | 2018-12-21 |
Family
ID=64758078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811006091.4A Pending CN109045077A (en) | 2018-08-30 | 2018-08-30 | The anticancer usage of Heterostemonous Biebersteinia fat-soluble extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109045077A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102090620A (en) * | 2010-12-08 | 2011-06-15 | 江南大学 | Dictyophora indusiata fruiting body extract with antibacterial activity and uses thereof |
| CN104382966A (en) * | 2014-11-20 | 2015-03-04 | 光明乳业股份有限公司 | Method for extracting biebersteinia heterostemon general flavone |
| CN104523777A (en) * | 2014-12-16 | 2015-04-22 | 光明乳业股份有限公司 | Biebersteinia heterostemon total flavone extract as well as extraction method and application thereof |
-
2018
- 2018-08-30 CN CN201811006091.4A patent/CN109045077A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102090620A (en) * | 2010-12-08 | 2011-06-15 | 江南大学 | Dictyophora indusiata fruiting body extract with antibacterial activity and uses thereof |
| CN104382966A (en) * | 2014-11-20 | 2015-03-04 | 光明乳业股份有限公司 | Method for extracting biebersteinia heterostemon general flavone |
| CN104523777A (en) * | 2014-12-16 | 2015-04-22 | 光明乳业股份有限公司 | Biebersteinia heterostemon total flavone extract as well as extraction method and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| ALIREZA GOLSHAN ET AL.: "Effects of Biebersteinia multifida hydro-ethanol extract on proliferation and apoptosis of human prostate cancer and human embryonic kidney cells", 《AJP》 * |
| 张普照 等: "熏倒牛中黄酮类成分研究", 《中草药》 * |
| 张雷红等: "《天然药物化学》", 31 January 2017, 中国医药科技出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103494875B (en) | Application of cyclocarya paliurus extract in preparation of medicament for preventing and treating leukemia | |
| CA2911745C (en) | Pharmaceutical composition for promoting bone tissue formation, containing stauntonia hexaphylla leaf extract as active ingredient | |
| CN105330714A (en) | Novel limonin compound as well as preparation method and medical application thereof in treatment of prostatic cancer | |
| CN109045077A (en) | The anticancer usage of Heterostemonous Biebersteinia fat-soluble extract | |
| CN102424678A (en) | High-purity mangiferin prepared from leaves and twigs of aquilaria sinensis and preparation method thereof | |
| CN103073527B (en) | Diterpene Libertellenone G and preparation method and use thereof | |
| CN109045078A (en) | Heterostemonous Biebersteinia anticancer usage | |
| Jakovljević et al. | The potential use of Indigobush (Amorpha fruticosa L.) as natural resource of biologically active compounds | |
| JP2002302451A (en) | Scf binding inhibitor | |
| CN110257260A (en) | A kind of Rhizoma Atractylodis Macrocephalae endogenetic fungus and its application | |
| Tejaswini et al. | Phytochemical screening and antimicrobial activities of plant extract of Tridax procumbens | |
| CN105287474B (en) | The application of anisic acid para hydroxybenzene ethyl ester | |
| CN104782657A (en) | Plant destructive distillation liquid, its preparation and its application in improvement of content of effective components in hairy root of Salvia miltiorrhiza | |
| CN101603011A (en) | The method and the special strain therefore thereof that prepare the two glucosides of epipodophyllotoxin | |
| CN103408528A (en) | Chroman compound, as well as preparation method and application thereof | |
| CN104857036B (en) | A kind of extracting method and product of euscaphis konishii active material | |
| CN103804334A (en) | Method for extracting C15H18O5 from Cichorium glandulosum Boiss.et Hout and application of C15H18O5 | |
| CN103843927B (en) | Anti-radiation black tea beverage and preparation method thereof | |
| CN105213364B (en) | The application of khellactone | |
| CN105343052B (en) | The application of RADIX PEUCEDANI aglycon | |
| CN105748547A (en) | Method for separating active components from saussurea involucrata cell culture through extraction | |
| CN103882075A (en) | Process for obtaining ginkgolide B by utilizing tremella aurantialba strains to transform ginkgo biloba extracts | |
| CN105193787B (en) | The application of byak-angelicin | |
| CN110742837B (en) | Anti-inflammatory mask and preparation method thereof | |
| CN113262181B (en) | Chimonanthus salicifolius ferment and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181221 |